Pheast Therapeutics

In a BioHub Podcast episode, Pheast CEO Roy Maute discusses the company’s macrophage-focused approach to cancer immunotherapy, CD24 as an immune checkpoint target, and its lead antibody, PHST001.

The article reviews the history of macrophage-targeted cancer therapies and Pheast’s focus on CD24. It discusses clinical data for PHST001 and preclinical signals for PHST677, a CDH1 x Nectin-4 bispecific antibody drug conjugate.

Pheast Therapeutics CSO Roy Maute discusses PHST001, a CD24 antibody designed to reactivate macrophages and drive anti-cancer immune responses.

Drug Discovery World highlights emerging cancer treatment strategies in an AACR 2026 roundup, including induced proximity therapeutics, next-generation antibody-drug conjugates, and AI in drug discovery. The article also discusses funding headwinds facing oncology innovation.

Pheast Therapeutics is advancing its anti-CD24 antibody PHST001 into Phase I clinical trials to restore macrophage activity against solid tumors.

The page features Pheast Therapeutics news, press releases, and media coverage, including updates on PHST001 clinical trials and macrophage checkpoint therapy.

Pheast Therapeutics invites people to help develop new immunotherapies.

Pheast’s team includes leaders, scientists, and investors working on immuno-oncology therapeutics.

Pheast Therapeutics develops innate immune checkpoint inhibitors, including anti-CD24, to activate macrophages against aggressive cancers.

Pheast Therapeutics’ privacy practices cover the collection, use, and protection of personal data, data retention policies, and users’ rights.

Pheast Therapeutics presents preclinical data on **PHST001**, a first-in-class antibody targeting **CD24**, at the **Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting**. The therapy aims to restore immune recognition in the tumor microenvironment by inhibiting macrophage checkpoints. The poster session highlights early-stage findings on its mechanism of action in cancer treatment.

Oct 2026BioSpaceNews article

Pheast Therapeutics reports preclinical data in *Clinical Cancer Research* showing its lead therapy, **PHST001**, exhibits strong anti-tumor effects. The monoclonal antibody (anti-CD24 IgG4) targets macrophages to treat solid tumors and is now in **Phase 1 clinical trials**. The study provides foundational evidence supporting its mechanism in cancer immunotherapy.

Jul 2026BioSpaceNews article

Pheast Therapeutics showcases preclinical findings for **PHST677**, a bispecific antibody-drug conjugate (ADC) that simultaneously targets **CDH1 (E-cadherin)** and **Nectin-4**. The data highlight a novel design leveraging dual blockade mechanisms to potentially enhance therapeutic efficacy in preclinical models. The presentation occurred at the **PEGS Boston Summit 2026**.

May 2026BioSpaceNews article

Pheast Therapeutics presents Phase 1a trial data for its drug candidate **PHST001**, demonstrating early clinical activity and target engagement. The findings include a distinct safety profile, innate immune activation, and initial signs of efficacy. Researchers highlight PHST001’s differentiated pharmacologic behavior at the **American Association for Cancer Research (AACR) 2026** meeting.

Apr 2026BioSpaceNews article